Nature:SARS-CoV-2 multiple meso-antibody structures are analyzed to provide a basis for treatment.

The COVID-19 pandemic has created an urgent health crisis.
antibody (hNAbs) of SARS-CoV-2 prickly proteins targeted at the host ACE2 bind binding domain (RBD) showed therapeutic prospects and was undergoing clinical evaluation.
to determine the structural correlation between NEUTRAL SARS-CoV-2, researchers recently solved eight different new structures of COVID-19 hNAbs combined with SARS-CoV-2 hedgehogs or RBDs.
can be divided into several types of antibodies by structural comparison.
(1) VH3-53 hNAbs with short CDRH3s, blocking ACE2 only in combination with "up" RBDs; it can also come into contact with adjacent RBDs, (3) bind outside the ACE2 bit and identify the hNAbs of "up" and "down" RBDs, and (4) the previously described non-blocking ACE2, and bind only to the antibodies "on" RBDs. class
Class 2 antibodies consist of four hNAbs, whose surface bridging RBDs, including a VH3-53 hNAb, which uses a long CDRH3 adjacent to the hydrophobic tip bridge "down" RBDs, thereby locking the hedgehog protein into a closed image.
table/sub-bitmaps show little interaction with host-derived N-polysaccharose, and the contribution of antibody body type hypermnants to table contact is minimal.
affinity measurements and maps of naturally occurring and in-body-selected prickly protein mutants in 3D provide insight into the possibility of SARS-CoV-2 escaping from antibodies caused by or therapeutically transmitted during infection.
These classifications and structural analyses provide rules for assigning current and future human RBD-targeted antibodies to categories, assessing fanatical effects, recommending combinations for clinical use, and providing insights into the immune response to SARS-CoV-2.
.